Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review.
Baha' SharafRama AlMasriNayef Abdel-RazeqOsama SalamaIbrahim HamadMahmoud Abu NasserHikmat Abdel-RazeqPublished in: Clinical, cosmetic and investigational dermatology (2022)
CDK4/6 inhibitor-induced vitiligo is a rare and unpredictable adverse event. This case report highlights the rarity of this adverse event, the dilemma related to the optimal treatment, and decisions related to continuation, holding, or switching CDK4/6 inhibitors.